The shadow of generic rivalry has repeatedly loomed over copyright’s blockbuster drug, Sildenafil, triggering questions about the outlook of related drug stakes. While first years saw substantial returns, the intellectual property end has created the path for less expensive copies, likely lowering earnings and posing a significant risk for stakeh